Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Rhea-AI Summary

Neumora Therapeutics (Nasdaq: NMRA) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York.

A live webcast will be available on the company’s events and presentations page and a replay will be archived for up to 30 days.

News Market Reaction

-0.98%

1 alert

-0.98% News Effect

On the day this news was published, NMRA declined 0.98%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Summit date and time: February 11, 2026 at 4:00 p.m. ET Webcast archive period: 30 days Current share price: $2.04 +5 more

8 metrics

Summit date and time February 11, 2026 at 4:00 p.m. ET Guggenheim Emerging Outlook: Biotech Summit fireside chat

Webcast archive period 30 days Replay available on company website after event

Current share price $2.04 Pre-news market context

Today’s volume 344,343 shares Compared with 20-day average volume

20-day avg volume 2,150,972 shares Liquidity benchmark before this news

52-week high $3.25 Pre-news 52-week trading range

52-week low $0.611 Pre-news 52-week trading range

Market capitalization $336,478,113 Equity value before the conference announcement

Market Reality Check

Price: $1.96 Vol: Volume 344,343 is well be...

low vol

$1.96 Last Close

Volume Volume 344,343 is well below the 20-day average of 2,150,972, indicating limited trading interest ahead of this routine event update. low

Technical Shares at $2.04 are trading above the 200-day MA of $1.63, while still 37.23% below the $3.25 52-week high.

Peers on Argus

NMRA was up 3.03% pre-news with mixed moves among peers: ANNX +1.89%, VNDA +2.68...

NMRA was up 3.03% pre-news with mixed moves among peers: ANNX +1.89%, VNDA +2.68%, but TNXP -2.11%. No peers appeared in the momentum scanner and no same-day peer headlines were flagged, suggesting this conference update is stock-specific rather than part of a sector-wide move.

Historical Context

5 past events · Latest: Jan 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Pipeline strategy update	Positive	-1.5%	Outlined 2026 strategy, KOASTAL readouts, NMRA-215 plans, and cash runway.
Jan 05	Clinical data update	Positive	-1.5%	Reported positive NMRA-511 Phase 1b Alzheimer’s agitation signal-seeking results.
Nov 06	Earnings and update	Neutral	-1.5%	Q3 2025 results, cash of $171.5M, loan draw and pipeline milestones.
Nov 03	Conference participation	Neutral	-0.3%	Announced November 2025 investor conference appearances and webcast availability.
Oct 27	Trial initiation	Positive	+2.3%	Initiated Phase 1 SAD/MAD study of M4 PAM NMRA-898 for neuropsychiatric disorders.

Pattern Detected

Recent NMRA news, including clinical and pipeline positives, has often seen muted or negative next-day price reactions, even when updates appeared favorable.

Recent Company History

Over the last few months, Neumora has reported several notable developments. On Oct 27, 2025, it initiated a Phase 1 study of NMRA-898, which saw a positive +2.28% reaction. Earnings and a Q3 2025 update on Nov 6, 2025 highlighted a $171.5M cash position and pipeline milestones but coincided with a -1.53% move. Two positive NMRA-511 and 2026 pipeline strategy updates on Jan 5, 2026 also saw shares down ~1.5%. Today’s conference participation fits this pattern of informational updates around ongoing programs and investor outreach.

Market Pulse Summary

This announcement highlights Neumora’s participation in the Guggenheim Emerging Outlook: Biotech Sum...

Analysis

This announcement highlights Neumora’s participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, with a fireside chat on February 11, 2026 at 4:00 p.m. ET and a webcast archived for 30 days. It continues a pattern of conference engagement similar to November 2025 events. Given recent clinical and pipeline updates, investors may focus on how management messaging at such forums frames key programs and the existing $171.5M cash position noted in prior filings.

Key Terms

clinical-stage biopharmaceutical, webcast

2 terms

clinical-stage biopharmaceutical medical

"Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company..."

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

webcast technical

"A live webcast of the fireside chat will be available on the events and presentations section..."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York, NY.

A live webcast of the fireside chat will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.

Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com

FAQ

When will Neumora Therapeutics (NMRA) present at Guggenheim Emerging Outlook: Biotech Summit 2026?

Neumora will present on Wednesday, February 11, 2026 at 4:00 p.m. ET. According to the company, the presentation takes the form of a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York City.

How can investors watch the Neumora (NMRA) fireside chat on February 11, 2026?

Investors can watch via a live webcast on the company’s events and presentations webpage. According to the company, the webcast will stream live and serve as the official broadcast for the fireside chat.

Will a replay of the Neumora (NMRA) Guggenheim fireside chat be available after the event?

Yes, a replay will be available and archived for up to 30 days after the event. According to the company, the replay will be posted on the events and presentations section of its website for later viewing.

What topics will Neumora Therapeutics (NMRA) likely cover in its Guggenheim fireside chat?

The company will discuss its clinical-stage pipeline and novel mechanisms of action for underserved diseases. According to the company, the fireside chat will focus on recent developments and program-level updates relevant to investors.

Where can I find the Neumora (NMRA) webcast link for the Guggenheim summit?

The webcast link will be posted on Neumora’s events and presentations webpage on its investor site. According to the company, the page will host the live stream and the subsequent replay for up to 30 days.